Giotrif 40mg

Pharmaceutical company from Germany, which works in the field of pharmaceuticals production Boehringer Ingelheim / Boehringer Ingelheim Pharma GmbH & Co. KG. KG, has been founded in the late nineteenth century. Currently, it is in the top 20 companies in this industry that operate in many countries of the world. The scope of application of remedies that are produced by this corporation is very extensive. Among them, according to experts, is chemotherapy treatment of malignant tumors. One of the innovative remedies that currently have no analogues in the world is a tablet preparation for oral using of Giotrif 40 mg.

Brief instruction on the using of the remedy Giotrif.

In the instruction and description of the active agent of this agent, which is Afatinib, it is noted that its therapeutic effect on malignant cells is based on the specific inhibition of a specific enzyme, tyrosine kinase, which participates in the biochemical processes inside the cell. The purpose of the remedy is indicated in the treatment of non-small cell lung cancer at various stages with a specific genetic mutation of the epidermal growth factor receptor. By its group membership – it is an antineoplastic and immunomodulating agent.

Contraindications to the appointment of chemotherapy on the basis of Afatinib – the following:
Severe individual sensitivity to the components of the drug or to the active ingredient;
The patient’s age is up to eighteen years;
Stay in a state of pregnancy and breast-feeding;

Expressed changes in the hepatic parenchyma, which lead to significant disturbances in the functioning of the hepato – biliary system.
The remedy is prescribed by a physician – chemotherapist, who has sufficient experience in the use of tyrosine kinase inhibitors. Oral administration of tablets is performed on an empty stomach, once a day. The duration of treatment depends on the clinical condition of the patient and the response of the body to therapy. In the case of progression of the tumor or significant changes in the objective status of the patient, which are caused by a sharp significant intoxication, treatment should be discontinued.